ArticleAsian Pacific journal of cancer prevention : APJCP2025
Osteoprotegerin as a Potential Biomarker for Breast Cancer: A Study of Its Relationship with Bone Health, vitamin D, and Calcium Levels.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer continues to be a significant global health issue and is associated with various biological indicators, including osteoprotegerin (OPG), a glycoprotein involved in bone metabolism, tumor progression, and immunological modulation. This study examined the potential of OPG as a biomarker for breast cancer and its correlation with bone health, vitamin D levels, and calcium concentrations.
objectivesTo quantify serum OPG levels in breast cancer patients and assess its viability as a diagnostic biomarker. In addition, to evaluate vitamin D levels due to their established correlation with an increased cancer risk in cases of deficiency. The study also examined parathyroid hormone (PTH) and calcium levels in breast cancer patients.
methodsBlood samples were obtained from female volunteers at the Oncology Teaching Hospital, Medical City, Baghdad, Iraq (September 2023 - February 2024). The study comprised three cohorts: healthy controls (G1, n=40), newly diagnosed breast cancer patients (G2, n=45), and patients undergoing chemotherapy (G3, n=45). Serum concentrations of OPG, vitamin D, PTH, and calcium were quantified using ELISA methodologies.
resultsNo statistically significant variations in OPG levels were observed between the control and patient groups, indicating minimal bone resorption during the early stages of breast cancer. Vitamin D levels were markedly reduced in G2 compared with the control group, while G3 showed a modest increase in vitamin D levels attributable to supplementation. Increased PTH levels were observed in breast cancer patients, supporting prior research linking elevated PTH with increased cancer risk. No notable differences were found in serum calcium levels among the groups.
conclusionVitamin D and PTH levels are crucial in early-stage breast cancer development, underscoring the need for monitoring these factors and questioning the diagnostic efficacy of OPG alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.